Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling

• Principais autores: Jing Cui (Autor), Yao Guo (Autor), Heshui Wu (Autor), Jiongxin Xiong (Autor), Tao Peng (Autor)
• Formato: Livro
• Publicado em: BMC, 2021-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background Gemcitabine (GEM) resistance remains a significant clinical challenge in pancreatic cancer treatment. Here, we investigated the therapeutic utility of everolimus (Evr), an inhibitor of mammalian target of rapamycin (mTOR), in targeting the Warburg effect to overcome GEM resistanc...